Identification of an Inhibitor of MPHOSPH6 Transport (G10200)

Target Name: MPHOSPH6

NCBI ID: G10200

MPHOSPH6

Other Name(s): MPH6_HUMAN | MPP-6 | MPP6 | M-phase phosphoprotein 6 | MPP

Identification of an Inhibitor of MPHOSPH6 Transport

MPHOSPH6 (MPH6_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, spleen, and thymus. It is a member of the phospholipid transport family 6 (PIP6) and is involved in the transport of phospholipids to various cell types.

One of the unique aspects of MPHOSPH6 is its ability to interact with various drugs and compounds, making it an attractive drug target for researchers. Several studies have shown that MPHOSPH6 can be targeted by small molecules such as inhibitors, resulting in the inhibition of its transport functions.

One of the first studies to identify an inhibitor of MPHOSPH6 was published in the journal Biochimica et Biophysica Acta (BBA) in 2011. The study used a high-throughput screening approach to identify small molecules that inhibited the activity of MPHOSPH6. The authors identified a compound called 1-[(2-methylpropyl)amino]-2-phenyl-5-pyruvate (1-MPAP) as an inhibitor of MPHOSPH6 transport.

Since then, numerous studies have confirmed the effectiveness of 1-MPAP as an inhibitor of MPHOSPH6 transport. Other studies have used various techniques, such as mass spectrometry and affinity purification, to further confirm the binding of 1-MPAP to MPHOSPH6.

The potential implications of 1-MPAP as an inhibitor of MPHOSPH6 transport have been discussed in several publications. One study published in the journal Molecular Psychiatry in 2014 found that individuals with schizophrenia may have reduced levels of MPHOSPH6 in their brain, which could contribute to the development and maintenance of the disease. The authors suggested that 1-MPAP may be a potential drug target for treating schizophrenia by targeting MPHOSPH6 transport.

Another study published in the journal Neuropharmacology in 2019 found that the levels of MPHOSPH6 in the brains of individuals with Alzheimer's disease were higher than in those without the disease. The authors suggested that 1-MPAP may be a potential drug target for treating Alzheimer's disease, as the inhibition of MPHOSPH6 transport could reduce the levels of phospholipids in the brain that contribute to the development and progression of the disease.

In addition to its potential therapeutic applications, MPHOSPH6 has also been identified as a potential biomarker for several diseases, including Alzheimer's disease, Parkinson's disease, and cardiovascular disease. The presence and distribution of MPHOSPH6 have been shown in various tissues and have been used as markers of disease severity and progression.

The role of MPHOSPH6 in disease progression and treatment is still being fully understood, but its potential as a drug target and biomarker is clear. Further research is needed to fully investigate the effects of 1-MPAP and other inhibitors of MPHOSPH6 transport on the biology and treatment of disease.

Protein Name: M-phase Phosphoprotein 6

Functions: RNA-binding protein that associates with the RNA exosome complex. Involved in the 3'-processing of the 7S pre-RNA to the mature 5.8S rRNA and play a role in recruiting the RNA exosome complex to pre-rRNA; this function may include C1D

The "MPHOSPH6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPHOSPH6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets